Ertugliflozin and Topiramate Interaction
Drug interaction information between Ertugliflozin and Topiramate.
Ertugliflozin and Topiramate have a documented moderate interaction in FDA labeling.
FDA drug labeling documents a moderate-severity interaction between Ertugliflozin and Topiramate. Major interactions are generally avoided, moderate ones may need monitoring or a dose adjustment, and minor ones are usually low-risk. This page shows the documented mechanism and guidance. Label-documented interactions are not a complete safety review, so always confirm your own medications with a pharmacist or doctor. Educational information, not medical advice.
How They Interact
Topiramate affects how the body handles acid, which can increase the risk of a serious condition called lactic acidosis when combined with metformin.
What To Do
Your doctor should monitor you closely for side effects and may need to adjust your medication.
FDA Label Information
7 DRUG INTERACTIONS Table 3: Clinically Significant Drug Interactions with SEGLUROMET Carbonic Anhydrase Inhibitors Clinical Impact: The risk of lactic acidosis may increase due to concomitant use of Topiramate or other carbonic anhydrase inhibitors (e.g., zonisamide, acetazolamide or dichlorphenamide) with metformin.
Ertugliflozin Also Interacts With
- Metformin moderate
- Dolutegravir moderate
- Ranolazine moderate
- Cimetidine moderate
- Zonisamide moderate
Topiramate Also Interacts With
- Zonisamide moderate
- Alogliptin moderate
- Hydrochlorothiazide minor
- Amitriptyline minor
- Pioglitazone minor
Frequently Asked Questions
Can I take Ertugliflozin and Topiramate together?
This is a moderate interaction. Your doctor should monitor you closely for side effects and may need to adjust your medication.
How serious is the interaction between Ertugliflozin and Topiramate?
This interaction is classified as "moderate" severity by the FDA. Moderate interactions may worsen your condition or change how your medications work.
Why do Ertugliflozin and Topiramate interact?
Topiramate affects how the body handles acid, which can increase the risk of a serious condition called lactic acidosis when combined with metformin.
Understanding the Ertugliflozin and Topiramate Interaction
FDA-approved prescribing information for these two drugs flags their combination as a moderate-severity interaction. Ertugliflozin belongs to the SGLT2 Inhibitor class and Topiramate belongs to the Anticonvulsant class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: Topiramate affects how the body handles acid, which can increase the risk of a serious condition called lactic acidosis when combined with metformin. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.
Context around a specific patient determines real-world impact. Ertugliflozin has 8 total documented interactions on file in this dataset, and Topiramate has 30. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: Your doctor should monitor you closely for side effects and may need to adjust your medication. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.
An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Ertugliflozin or Topiramate based on a web page, speak with your prescriber or pharmacist before making any change.
Sources: FDA Drug Labels (SPL) via openFDA (2026). This is for informational purposes only and is not medical advice. Always consult your healthcare provider about drug interactions.
Read our methodology - how this data is sourced, computed, and verified.